Compare · ABT vs AUPH
ABT vs AUPH
Side-by-side comparison of Abbott Laboratories (ABT) and Aurinia Pharmaceuticals Inc (AUPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AUPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 81.4x AUPH ($2.23B).
- ABT has hit the wire 11 times in the past 4 weeks while AUPH has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 15 for AUPH).
- Company
- Abbott Laboratories
- Aurinia Pharmaceuticals Inc
- Price
- $104.88+0.16%
- $16.52-1.17%
- Market cap
- $181.14B
- $2.23B
- 1M return
- -
- -2.51%
- 1Y return
- -
- +39.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest AUPH
- Chief Legal Officer Robertson Stephen P. sold $190,427 worth of shares (11,939 units at $15.95), decreasing direct ownership by 2% to 588,848 units (SEC Form 4) to cover withholding tax
- Chief Legal Officer Robertson Stephen P. sold $355,946 worth of shares (20,975 units at $16.97), decreasing direct ownership by 3% to 600,787 units (SEC Form 4) to cover withholding tax
- Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Aurinia Settles Patent Litigation with Teva
- SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc
- Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
- Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
- SEC Form 4 filed by Director Johnson Craig A
- SEC Form 4 filed by Director Goetz Kathleen